Clinical Question
Does ipamorelin offer a more selective growth hormone (GH) secretagogue profile compared to predecessors, and what is the current strength of evidence for its proposed clinical indications?
Evidence Snapshot
- Compound Type: Selective pentapeptide ghrelin receptor agonist (GHS-R1a).
- Evidence Grade: B-.
- Pharmacokinetics: Discrete GH pulses with an approximate 2-hour half-life via intravenous administration.
- Clinical Outcomes: Negative result for postoperative ileus (Phase II, PMID: 25249181).
- Regulatory Status: Not FDA-approved; currently listed under Category 2 for 503b compounding; WADA prohibited.
What the Research Shows
Ipamorelin was the first compound documented as a truly selective growth hormone secretagogue. Unlike earlier agents in its class, its activity is characterized by mimicking natural GH pulsatility rather than maintaining a sustained elevation of growth hormone levels.
In human clinical trials, the research has primarily focused on gastrointestinal indications. A Phase II clinical trial (NCT00672074) was completed evaluating the peptide for the treatment of postoperative ileus. However, the published results (PMID: 25249181) indicate a negative outcome, as the compound failed to meet its primary gastrointestinal endpoint.
While ipamorelin is frequently discussed in clinical settings for other purposes, there are currently no published randomized controlled trials (RCTs) demonstrating efficacy for body composition changes, fat loss, or athletic performance outcomes. Furthermore, the common practice of stacking ipamorelin with CJC-1295 is not supported by any RCT evidence in the literature.
Mechanism
Ipamorelin functions as a selective pentapeptide ghrelin receptor agonist (GHS-R1a). It is specifically designed to trigger short, discrete GH pulses. The mechanism is distinct in its selectivity; unlike other secretagogues, ipamorelin does not affect the levels of cortisol, prolactin, or adrenocorticotropic hormone (ACTH). This selectivity allows for the stimulation of growth hormone release without the concomitant activation of other pituitary hormones or the stress response axis.
Limitations of the Evidence
The evidence for ipamorelin remains limited by the lack of successful clinical applications. The primary Phase II study failed its clinical endpoint for gastrointestinal motility. There is a total absence of peer-reviewed human data regarding its utility for performance enhancement or metabolic health.
From a regulatory and safety perspective, the FDA has flagged concerns regarding the safety of compounding this peptide. It was moved to Category 2 for 503a and 503b compounding in September 2023, and although its nomination was withdrawn for 503a in September 2024, it remains under regulatory scrutiny. Additionally, a warning letter was issued to Tailor Made in 2020. The World Anti-Doping Agency (WADA) has added ipamorelin to its list of prohibited substances, further complicating its clinical profile for athletic populations.
Clinical Takeaway
Ipamorelin is a highly selective GH secretagogue that effectively mimics physiological GH pulsatility without influencing ACTH, cortisol, or prolactin levels. However, its clinical utility is currently unproven, as it failed to demonstrate efficacy in Phase II trials for postoperative ileus. Physicians should be aware of the total lack of RCT evidence for body composition or its use in combination with other peptides, as well as its restrictive regulatory and WADA status.
Sources
- Clinical Trial NCT00672074 (PMID: 25249181)
- FDA Regulatory Status Data (March 2026)
- TruthTides GH Secretagogue Mechanism Database
- FDA Warning Letter (2020) — Tailor Made
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.